Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBeximco Pharma Regulatory News (BXP)

  • This share is currently suspended. It was suspended at a price of 42.50

Share Price Information for Beximco Pharma (BXP)

Share Price is delayed by 15 minutes
Get Live Data
42.50    0.00 (0.00%)
Bid:
0.00
Ask:
0.00
Spread: 0.00 (0.00%)
Market Cap: £189.60m
BXP Live PriceLast checked at - London Stock Exchange

Intraday Beximco Pharma Share Chart

Notice of AGM

11 May 2010 07:00

RNS Number : 6697L
Beximco Pharmaceuticals Ltd
11 May 2010
 



BEXIMCO PHARMACEUTICALS LTD.

 

11 May, 2010

 

AGM Notification

 

Notice is hereby given that the 34th Annual General Meeting of the Shareholders of Beximco Pharmaceuticals Limited will be held on Tuesday, 15th June, 2010 at 10.00 a.m. at Beximco Industrial Park, Sarabo, Kashimpur, Gazipurto transact the following business:

 

AGENDA

1. To receive, consider and adopt the Audited Financial Statements of the Company for the year ended 31st December, 2009 together with reports of the Auditors and the Directors thereon

2. To elect Directors

3. To declare 15% Stock Dividend

4. To appoint Auditors for the year 2010 and to fix their remuneration

5. To transact any other business of the Company with the permission of the Chair

 

By order of the Board

 

 

MD. ASAD ULLAH, FCS

Executive Director & Company Secretary

 

 

NOTES:

(1) The Record Date shall be on 19th May, 2010. The Shareholders whose names will appear in the Share Register of the Company or in the Depository Register on that date will be entitled to attend at the Annual General Meeting and to receive the dividend.

 

(2) A member entitled to attend and vote at the General Meeting may appoint a Proxy to attend and vote in his/her stead. The Proxy Form, duly stamped, must be deposited at the Registered office of the Company not later than 48 hours before the time fixed for the meeting.

(3) Admission to the meeting room will be strictly on production of the attendance slip sent with the Notice as well as verification of signature of Member(s) and/or proxy-holder(s)

 

(4) No gift or benefit in cash or kind shall be paid to the holders of equity securities in terms of Clause (c) of the Notification No.SEC/SRMI/2000-953/1950 dated 24 October 2000 for attending this AGM of the Company.

 

For further enquiries please visit www.beximco-pharma.com or contact:

 

Beximco Pharma

Nazmul Hassan MP, Managing Director

Tel: +880 2 861 9151, ext.2080

 

Md. Asad Ullah, FCS, Executive Director & Company Secretary

Tel; +880 2 8618220-1, Ext 1140

 

Libertas Capital

Jakob Kinde / Anthony Rowland

Tel: +44 (0)20 7569 9650

 

Financial Dynamics

Jonathan Birt / Susan Quigley

Tel: +44 (0)20 7269 7169

 

Notes to Editors

 

About Beximco Pharmaceuticals Limited

Founded in 1976 and based in Dhaka, Bangladesh, BPL manufactures and sells generic pharmaceutical formulation products, active pharmaceutical ingredients and intravenous fluids. The Company also manufactures and markets its own branded generics for almost all diseases. The Company also undertakes contract manufacturing for multinational pharmaceutical companies. The Company operates from a 20 acre site in Dhaka and currently employs over 2,400 staff.

 

The Company's products are sold to retail outlets, medical institutions and other pharmaceutical manufacturers in Bangladesh, in regional markets such as Sri Lanka, Nepal, Bhutan, Vietnam, Cambodia and Myanmar and in other markets overseas, principally in East Africa, Pacific Island and Central American countries and South East Asia, including Singapore and Hong Kong.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
NOAURVARRSAVAUR
Date   Source Headline
5th Mar 20269:13 amRNSUpdate on Writ Petitions
28th Jan 20262:01 pmRNSOrder re Extension to Publish Financial Results
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
2nd Jan 20267:30 amRNSSuspension - Beximco Pharmaceuticals PLC
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
19th Dec 202511:00 amRNSDelay in Results & Temporary Suspension
13th Nov 20254:00 pmRNSRequest of Extension to Publish Q1 Results
4th Nov 20257:00 amRNSChange of Name to Beximco Pharmaceuticals PLC.
27th Oct 20253:53 pmRNSRequest of Extension to Publish Financial Results
24th Oct 20257:00 amRNS-RAffordable treatment option for cystic fibrosis
15th Sep 20251:17 pmRNSFurther update on BSEC Order
21st May 20253:18 pmRNSUpdate on BSEC Order
28th Apr 20257:00 amRNSRequest of Extension to Publish Q3 Results
21st Mar 20253:51 pmRNSResponse to media reports and update on BSEC order
6th Mar 20257:00 amRNSUpdate on BSEC order
30th Jan 20252:59 pmRNSPayment of Cash Dividend
29th Jan 20257:01 amRNSBoard Changes
29th Jan 20257:00 amRNSHalf Year Results 2024-25
14th Jan 202511:24 amRNSBoard of Directors
30th Dec 20247:00 amRNSAnnual General Meeting Statement
19th Nov 20247:00 amRNSAGM Notification
14th Nov 20247:00 amRNSFinancial Results for the First Quarter
12th Nov 202410:00 amRNSRestoration - Beximco Pharmaceuticals Limited
12th Nov 202410:00 amRNSUpdate on Interim Order Supreme Court decision
11th Nov 202411:01 amRNSFurther re the Temporary Suspension of Trading
11th Nov 20247:30 amRNSSuspension - Beximco Pharmaceuticals Limited
7th Nov 20247:00 amRNSResults for the year ended 30 June 2024
29th Oct 20247:00 amRNSNotification of Preliminary Results and AGM
28th Oct 20242:35 pmRNSUpdate on Writ Petition and Interim Order
2nd Oct 20247:00 amRNSUpdate on Writ Petition and Interim Order
30th Sep 20247:06 amRNSClarification on Writ Petition
6th Sep 20242:17 pmRNSUpdate regarding Vice-Chairman, Salman Rahman
3rd Sep 20241:45 pmRNSCorrection and Clarification of Press Commentary
15th Aug 20247:00 amRNSStatement regarding Vice-Chairman, Salman Rahman
13th Aug 20247:00 amRNSStatement on political and business situation
30th Apr 20247:00 amRNSQ3 Financial Results
4th Mar 20247:00 amRNSAppointment of Managing Director
30th Jan 20247:00 amRNSHalf Year Results 2023-24
25th Jan 20249:53 amRNSPayment of Cash Dividend
11th Jan 202411:44 amRNSBoard Change
28th Dec 20239:40 amRNSAGM Statement
6th Nov 202312:17 pmRNSNotice of AGM
6th Nov 20237:00 amRNSFinancial Results for the First Quarter
1st Nov 20237:00 amRNSResults for the year ended 30 June 2023
20th Oct 20237:00 amRNSNotification of Preliminary Results and AGM
11th Sep 202310:17 amRNSClarification on Press Report
31st Aug 20233:51 pmRNSRe-appointment of Independent Director
2nd May 20237:00 amRNSQ3 Financial Results
11th Apr 20233:59 pmRNSHoldings in Company
31st Mar 202311:03 amRNSHoldings in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.